Picard Medical, Inc. (PMI) Stock Price & Analysis
Picard Medical, Inc. (PMI) rose 0.00% to USD 0.09 as of July 25, 2026 at 21:57 UTC, according to Nexqual real-time market data.
PMI last closed at USD 0.09; the session ranged USD 0.09–0.1 on volume of 6,869,659 shares. Market capitalization is $9.03M, with a 52-week range of USD 0.09–13.68 (ASE). Source: Nexqual, July 25, 2026 at 21:57 UTC.
Key Statistics (as of July 25, 2026 at 21:57 UTC)
| Price | USD 0.09 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0.09 |
| Open | USD 0.09 |
| Day Range | USD 0.09 – 0.1 |
| 52-Week Range | USD 0.09 – 13.68 |
| Volume | 6,869,659 shares |
| Market Cap | $9.03M |
| Exchange | ASE |
Technical Analysis (PMI)
Nexqual's technical model rates PMI "SELL" based on 3 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 21:57 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 29.34 (oversold) |
| vs SMA50 | Below (USD 0.17) |
| MACD | -0.03 (negative) |
Analyst Ratings (PMI)
Wall Street analysts rate PMI "None", per Nexqual as of July 25, 2026 at 21:57 UTC.
| Consensus Rating | None |
|---|---|
| Buy / Hold / Sell | 0 / 1 / 0 |
Earnings (PMI)
| Next Earnings Date | 2026-08-14 |
|---|---|
| EPS Estimate | USD -0.03 |
| Revenue Estimate | $1.55M |
Source: Nexqual, July 25, 2026 at 21:57 UTC.
Financials & Fundamentals (PMI)
| Total Revenue | $5.47M |
|---|---|
| Revenue Growth (YoY) | +85.50% |
| Gross Margin | +7.84% |
| Operating Margin | -392.26% |
| Profit Margin | +0.00% |
| Current Ratio | 0.75 |
| Total Cash | $121,000 |
| Total Debt | $3.27M |
| Free Cash Flow | $-15.29M |
Source: Nexqual, July 25, 2026 at 21:57 UTC.
Financial Health Score (PMI)
Nexqual rates Picard Medical, Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 21:57 UTC.
| Growth | Strong — Revenue +86% YoY (latest Q) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $121K cash vs $3M debt |
| Cash Flow | Weak — Operating cash flow -$17M |
| Efficiency | Mixed — No data |
Ownership (PMI)
| Insider Ownership | +47.67% |
|---|---|
| Institutional Ownership | +9.77% |
| Shares Outstanding | 102.70M |
| Float | 39.51M |
| Short % of Float | +24.41% |
Source: Nexqual, July 25, 2026 at 21:57 UTC.
Leadership (PMI)
Picard Medical, Inc. is led by Yuncai Fang (age 59), Interim CEO & Chairman of the Board, per Nexqual as of July 25, 2026 at 21:57 UTC.
| Interim CEO & Chairman of the Board | Yuncai Fang (age 59) |
|---|---|
| Chief Operating Officer | Matthew Schuster (age 44) |
| Chief Technology Officer of SynCardia Systems, LLC | Frank Tinker (age 69) |
From Picard Medical, Inc.'s Latest SEC 10-K Filing (filed 2026-03-30)
Key Strengths & Strategy (as disclosed to the SEC)
- Picard Medical, Inc., together with its subsidiaries, engages in the designing, manufacturing, production, supply, marketing, and sale of medical device products.
- The company offers SynCardia TAH, an artificial heart for patients that is designed to function as a failed human heart in patients suffering from advanced heart failure.
- The company operates in the United States, Europe, and internationally.
- Picard Medical, Inc. operates as a subsidiary of Hunniwell Picard I, Llc.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RDN | Radian Group Inc. | USD 38.68 | ▲ 1.18% |
| MTG | MGIC Investment Corporation | USD 29.65 | ▲ 2.1% |
| MBI | MBIA Inc. | USD 5.66 | ▼ 5.82% |
| TGIC | TRIAD GUARANTY INC | USD 0 | ▲ 0% |
| PRE | Prenetics Global Limited | USD 18.74 | ▼ 14.27% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 21:57 UTC. This page is informational and not investment advice.